A world-class biopharmaceutical manufacturing campus (Biopharma Campus) will be established in Abu Dhabi that will tap into the global state-of-the-art vaccine and therapeutic products to strengthen regional supply chains and drive forward the nation’s diversification and economic growth agenda.
This follows an agreement between Mubadala Investment Company and G42, the leading UAE-based AI and cloud computing company. The campus will invest in and establish multiple biopharma initiatives, leveraging the expertise of Mubadala’s advanced manufacturing companies as well as G42’s leading capabilities in artificial intelligence and cloud computing.
Also Read: Fueling The World, One Insight At A Time
“Through the establishment of this campus in partnership with G42 and our group companies, we are investing in innovation and reinforcing Abu Dhabi’s rapidly developing life sciences ecosystem. Bringing cutting-edge manufacturing technologies to the UAE will not only strengthen our nation’s biopharma supply chain and pandemic response but provide opportunities for local talent development and long-term, sustainable economic growth,” said Musabbeh Al Kaabi, Chief Executive Officer of UAE Investments, Mubadala.
The world-class Biopharma Campus will focus on end-to-end manufacturing of state-of-the-art biologics and host anchor partnerships with Contract Manufacturing and Development Organisations (CDMOs). A CDMO model enables manufacturers to work with multiple innovators, reducing product risk and enabling economies of scale.
